This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nuermberger, E. L. Articles by Grosset, J. H. Search for Related Content PubMed PubMed Citation Articles by Nuermberger, E. L. Articles by Grosset, J. H.

Paucibacillary Tuberculosis in Mice after Prior Aerosol Immunization with Mycobacterium bovis BCG

Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland

Received 9 September 2003/ Returned for modification 20 October 2003/ Accepted 24 October 2003

To develop a murine model of paucibacillary tuberculosis for experimental chemotherapy of latent tuberculosis infection, mice were immunized with viable Mycobacterium bovis BCG by the aerosol or intravenous route and then challenged six weeks later with virulent Mycobacterium tuberculosis. The day after immunization, the counts were 3.71 ± 0.10 log₁₀ CFU in the lungs of aerosol-immunized mice and 3.65 ± 0.11 and 4.93 ± 0.07 log₁₀ CFU in the lungs and spleens of intravenously immunized mice, respectively. Six weeks later, the lungs of all BCG-immunized mice had many gross lung lesions and splenomegaly; the counts were 5.97 ± 0.14 and 3.54 ± 0.07 log₁₀ CFU in the lungs and spleens of aerosol-immunized mice, respectively, and 4.36 ± 0.28 and 5.12 ± 0.23 log₁₀ CFU in the lungs and spleens of intravenously immunized mice, respectively. Mice were then aerosol challenged with M. tuberculosis by implanting 2.37 ± 0.13 log₁₀ CFU in the lungs. Six weeks after challenge, M. tuberculosis had multiplied so that the counts were 6.41 ± 0.27 and 4.44 ± 0.14 log₁₀ CFU in the lungs and spleens of control mice, respectively. Multiplication of M. tuberculosis was greatly limited in BCG-immunized mice. Six weeks after challenge, the counts were 4.76 ± 0.24 and 3.73 ± 0.34 log₁₀ CFU in the lungs of intravenously immunized and aerosol-immunized mice, respectively. In contrast to intravenously immunized mice, there was no detectable dissemination to the spleen in aerosol-immunized mice. Therefore, immunization of mice with BCG by the aerosol route prior to challenge with a low dose of M. tuberculosis resulted in improved containment of infection and a stable paucibacillary infection. This model may prove to be useful for evaluation of new treatments for latent tuberculosis infection in humans.

Editor: W. A. Petri, Jr.

This article has been cited by other articles:

• Nuermberger, E., Tyagi, S., Williams, K. N., Rosenthal, I., Bishai, W. R., Grosset, J. H. (2005). Rifapentine, Moxifloxacin, or DNA Vaccine Improves Treatment of Latent Tuberculosis in a Mouse Model. Am. J. Respir. Crit. Care Med. 172: 1452-1456 [Abstract] [Full Text]  
• Tyagi, S., Nuermberger, E., Yoshimatsu, T., Williams, K., Rosenthal, I., Lounis, N., Bishai, W., Grosset, J. (2005). Bactericidal Activity of the Nitroimidazopyran PA-824 in a Murine Model of Tuberculosis. Antimicrob. Agents Chemother. 49: 2289-2293 [Abstract] [Full Text]